Psychotropic Medication Use for Adults with Autism Spectrum Disorder who Receive Services and Supports Through Adult Developmental Disability Services in the United States

2019 ◽  
Vol 49 (6) ◽  
pp. 2291-2303 ◽  
Author(s):  
Amy Esler ◽  
Amy Hewitt ◽  
Jennifer Hall-Lande ◽  
Sandra L. Pettingell ◽  
James Houseworth
Keyword(s):  
United States ◽  
Autism Spectrum Disorder ◽  
Developmental Disability ◽  
Psychotropic Medication ◽  
Medication Use ◽  
The United States ◽  
Autism Spectrum ◽  
Disability Services ◽  
Adults With Autism ◽  
Services And Supports

scholarly journals Neuropsychiatric profile and psychotropic medication use in adults with autism spectrum disorder: results from the Australian Longitudinal Study of Adults with Autism

BJPsych Open ◽  
2018 ◽  
Vol 4 (6) ◽  
pp. 461-466 ◽  
Author(s):  
Rachael C. Cvejic ◽  
Samuel R. C. Arnold ◽  
Kitty-Rose Foley ◽  
Julian N. Trollor
Keyword(s):  
Autism Spectrum Disorder ◽  
Longitudinal Study ◽  
Psychotropic Medication ◽  
Medication Use ◽  
Autism Spectrum ◽  
Spectrum Disorder ◽  
Limited Evidence ◽  
Adults With Autism ◽  
Adolescents With Autism ◽  
Adults With Asd

BackgroundChildren and adolescents with autism spectrum disorder (ASD) are a highly medicated group. Few studies have examined the neuropsychiatric profile and patterns of psychotropic medication use among adults with ASD.AimsTo describe and compare the neuropsychiatric profile and psychotropic medication use in a cohort of adults with ASD and non-autistic controls.MethodBaseline data from a survey-based, longitudinal study of adults with ASD in Australia. Participants were 188 adults with ASD and 115 controls aged 25–80 years.ResultsASD was associated with increased odds of psychotropic medication use even when controlling for the presence of any neurological or psychiatric disorder. There were no corresponding indications for 14.4% of psychotropic medications prescribed to adults with ASD.ConclusionsThis study found substantial psychotropic prescribing for adults with ASD. Patterns of psychotropic medication use may reflect prescribing for behavioural indications despite limited evidence to support this practice.Declaration of interestNone.

Characteristics of adults with autism spectrum disorder who use adult developmental disability services: Results from 25 US states

2012 ◽  
Vol 6 (2) ◽  
pp. 741-751 ◽  
Author(s):  
Amy S. Hewitt ◽  
Roger J. Stancliffe ◽  
Annie Johnson Sirek ◽  
Jennifer Hall-Lande ◽  
Sarah Taub ◽  
...  
Keyword(s):  
Autism Spectrum Disorder ◽  
Developmental Disability ◽  
Autism Spectrum ◽  
Spectrum Disorder ◽  
Disability Services ◽  
Adults With Autism ◽  
Us States

Ten weeks in: COVID-19-related distress in adults with autism spectrum disorder

Autism ◽  
2021 ◽  
pp. 136236132110059
Author(s):  
Ryan E Adams ◽  
Shuting Zheng ◽  
Julie Lounds Taylor ◽  
Somer L Bishop
Keyword(s):  
Mental Health ◽  
United States ◽  
Autism Spectrum Disorder ◽  
Negative Impact ◽  
The United States ◽  
Autism Spectrum ◽  
Anxiety Symptoms ◽  
Spectrum Disorder ◽  
Adults With Autism ◽  
Health Symptoms

This study examined COVID-19-related distress among adults with autism spectrum disorder and its associations with demographic and mental health information. A sample of 275 adults (ages 18–35) in the United States, all capable of providing self-reports, was recruited from a large national registry. Adults completed online surveys of mental health symptoms just before COVID-19 was declared a pandemic. Two months later, they completed the same surveys of mental health symptoms, and also reported about distress they had experienced as a result of the COVID-19 pandemic. Nearly two-thirds (65.9%) endorsed some form of COVID-related distress with a little over half reporting any individual form of distress. Although depressive and anxiety symptoms did not change from Time 1 to Time 2 on average, higher levels of COVID-related distress was associated with an increase in depressive and anxiety symptoms between Time 1 and Time 2. In addition, women and those who reported higher anxiety symptoms before the pandemic were more likely to report some form of COVID-related distress. The findings suggest that as this global crisis continues to unfold, it will be critical to ensure that adults with autism spectrum disorder who were experiencing mental health challenges prior to the pandemic receive appropriate monitoring. Lay abstract This study used data collected from 275 adults in the United States with autism spectrum disorder both before the pandemic and then 10 weeks into the pandemic to assess COVID-19-related distress and its impact. Two-thirds of those surveyed reported some type of distress related to the pandemic (i.e. difficulty coping or negative impact on emotional and mental health). While there were no changes in depressive and anxiety symptoms from prior to COVID-19 to 10 week later in the group as a whole, self-reported distress predicted increases in both anxiety and depression across the two timepoints. Furthermore, adults with higher levels of anxiety prior to the pandemic were more likely to report distress, and women were more likely to report a negative impact of the pandemic on their emotional and mental health. Findings highlight the importance of monitoring with adults with autism spectrum disorder to assess their need for mental health support, and providing ongoing support to those who already experience anxiety even before the pandemic.

Psychotropic Medication Use in Adolescents With Autism Spectrum Disorder

2012 ◽  
Author(s):  
Melissa P. Maye ◽  
Timothy W. Soto ◽  
Frances Martinez-Pedraza ◽  
Deborah K. Anderson ◽  
Catherine Lord ◽  
...  
Keyword(s):  
Autism Spectrum Disorder ◽  
Psychotropic Medication ◽  
Medication Use ◽  
Autism Spectrum ◽  
Spectrum Disorder ◽  
Adolescents With Autism

Improving psychotropic medication use among persons with dementia

2016 ◽  
Vol 28 (10) ◽  
pp. 1587-1588 ◽  
Author(s):  
Donovan T. Maust
Keyword(s):  
United States ◽  
Older Adults ◽  
Nursing Home ◽  
Psychotropic Medication ◽  
Medication Use ◽  
The United States ◽  
Black Box ◽  
Community Settings ◽  
Limited Evidence

The use of psychotropic medication among persons with dementia (PWD) both in nursing home (Wetzels et al., 2011) and community settings (Maust et al., 2016) far exceeds what might be expected based on their limited evidence for benefit (Kales et al., 2015). This relatively high use persists despite years of evidence about the potential harms associated with their use in older adults generally and PWD in particular (e.g. Wang et al., 2001; Schneider et al., 2005). However, the solution to relatively high psychotropic use is not to end all psychotropic use, as there are individual patients for whom use of such medication is appropriate. For example, a policy that defines all antipsychotic use as inappropriate may simply lead to increased use of alternatives with even less evidence of benefit, as suggested by the response to antipsychotics’ black box warning in the United States (Kales et al., 2011).

Therapy and Psychotropic Medication Use in Young Children With Autism Spectrum Disorder

PEDIATRICS ◽  
2020 ◽  
Vol 145 (Supplement 1) ◽  
pp. S99-S107 ◽  
Author(s):  
Daniela Ziskind ◽  
Amanda Bennett ◽  
Abbas Jawad ◽  
Nathan Blum
Keyword(s):  
Autism Spectrum Disorder ◽  
Young Children ◽  
Psychotropic Medication ◽  
Medication Use ◽  
Children With Autism ◽  
Autism Spectrum ◽  
Spectrum Disorder ◽  
Young Children With Autism
Sign in / Sign up

Export Citation Format

Share Document